Nicotinamide mononucleotide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-07-29. Anything still debated is marked as such rather than presented as settled.
Nicotinamide mononucleotide, commonly abbreviated NMN, is a naturally occurring nucleotide found in the cells of many organisms. Its structure consists of a nicotinamide group linked to a ribose sugar that carries a phosphate group. NMN is an intermediate in the biosynthesis of nicotinamide adenine dinucleotide, or NAD+, a coenzyme involved in many metabolic reactions. The abbreviation usually refers to the beta anomer, though related forms can exist. In scientific literature, NMN is distinct from nicotinamide riboside, another NAD+ precursor.
In the NAD+ salvage pathway, the enzyme NAMPT converts nicotinamide and a phosphate-donor molecule into NMN. A second enzyme, NMNAT, then converts NMN into NAD+. Nicotinamide riboside can also enter this route after being converted to NMN by nicotinamide riboside kinases. Because NMN sits at a junction between precursor uptake and NAD+ formation, its cellular concentration is tightly linked to enzyme activity and tissue type. NAD+ participates in redox reactions, signaling, and DNA repair, and its levels decline with age in some animal models, though human evidence remains more limited and context-dependent.
Research interest in NMN increased after animal studies reported that oral or injected NMN can raise NAD+ levels in some tissues. How NMN is absorbed and distributed in humans is not fully established. Some evidence suggests extracellular NMN may be dephosphorylated to nicotinamide riboside before cellular uptake, while other studies propose specific transport routes. Direct human data on these mechanisms remain limited. Regulatory status also varies: in some countries NMN is treated as a dietary supplement, while elsewhere it is restricted or requires approval, and these differences affect labeling, sale, and research.
Nicotinamide mononucleotide, usually shortened to NMN, is a naturally occurring nucleotide. Its structure consists of a nicotinamide base linked to a ribose sugar that carries a phosphate group. In cells, NMN serves as an intermediate in the salvage pathway that produces nicotinamide adenine dinucleotide, or NAD+. Because NAD+ participates in many oxidation-reduction reactions, NMN sits near central metabolic processes. The compound is not a drug in most jurisdictions and is discussed mainly in biochemistry and nutrition research.
The term NMN commonly refers to the beta isomer, in which the nicotinamide group is attached to the ribose through a beta-glycosidic bond. Commercial material may be supplied as the free acid or as a salt, such as a sodium salt, which affects molecular weight and water solubility. Related compounds include nicotinamide riboside and NAD+ itself, but these are distinct molecules with different formulas and cellular handling. Laboratory research often uses the beta form because it matches the naturally occurring configuration found in biological systems.
Small amounts of NMN occur in some foods, including certain vegetables, fruits, and animal products, though the quantities are generally low and variable. Human cells also synthesize NMN internally from nicotinamide and other precursors. Research interest increased after studies examined whether raising NAD+ levels affects metabolism and aging-related pathways in animals. Evidence in humans remains limited and mixed for many outcomes, and questions about effective absorption, tissue delivery, and long-term effects are still open. Regulatory status differs by country, with some markets treating NMN as a supplement ingredient and others restricting its sale.
| Property | Value | Notes |
|---|---|---|
| Chemical name | Nicotinamide mononucleotide | Common name; beta form often denoted beta-NMN |
| Chemical formula | C11H15N2O8P | As free acid; salt forms differ |
| Molar mass | 334.22 g/mol | Calculated for the free acid |
| CAS Registry Number | 1094-61-7 | For beta-nicotinamide mononucleotide |
| Biochemical role | NAD+ intermediate | Participates in the salvage biosynthesis pathway |
Nicotinamide mononucleotide, commonly abbreviated NMN, is a naturally occurring nucleotide. Its structure combines a nicotinamide ring with a ribose sugar and a phosphate group. The compound appears in cells across many organisms as an intermediate in the production of nicotinamide adenine dinucleotide, or NAD+. Because NMN sits close to NAD+ in metabolism, it has drawn interest in biochemistry and aging research. The molecule is not a dietary essential nutrient in the classical sense, and its presence in food is generally low and variable.
NAD+ serves as a coenzyme in redox reactions and as a substrate for enzymes involved in DNA repair and cellular signaling. In the salvage pathway, nicotinamide is converted to NMN by the enzyme NAMPT. NMN is then converted to NAD+ by NMNAT enzymes. A separate route links nicotinamide riboside to NMN through phosphorylation. These pathways maintain NAD+ levels, which can decline with age or metabolic stress in some tissues. The relative contribution of circulating NMN to tissue NAD+ remains an active area of study.
Natural sources of NMN include mammals, plants, and microorganisms, where it functions as an intermediate in NAD+ salvage and biosynthesis pathways. In mammals, the enzyme nicotinamide phosphoribosyltransferase produces NMN from nicotinamide and phosphoribosyl pyrophosphate. NMN is then converted to NAD+ by nicotinamide mononucleotide adenylyltransferase. Some foods contain measurable NMN, but reported amounts vary widely by species, tissue, and analytical method. The extent to which dietary NMN contributes to cellular NAD+ pools remains an open research question.
Chemically, NMN is described by the molecular formula C11H15N2O8P and a molecular mass near 334.22 g/mol. The beta anomer has a CAS Registry Number of 1094-61-7. It is typically supplied as a white to off-white powder for laboratory use. The molecule carries a phosphate group and a positively charged nicotinamide ring, giving it polar and water-soluble character. These properties influence how it is detected, purified, and stored in research and analytical laboratories.
== Function == Angiogenin is a key protein implicated in angiogenesis in normal and tumor growth. Angiogenin interacts with endothelial and smooth muscle cells resulting in cell migration, invasion, proliferation and formation of tubular structures. Ang binds to actin of both smooth muscle and endothelial cells to form complexes that activate proteolytic cascades which upregulate the production of proteases and plasmin that degrade the laminin and fibronectin layers of the basement membrane. Degradation of the basement membrane and extracellular matrix allows the endothelial cells to penetrate and migrate into the perivascular tissue. Signal transduction pathways activated by Ang interactions at the cellular membrane of endothelial cells produce extracellular signal-related kinase1/2 (ERK1/2) and protein kinase B/Akt. Activation of these proteins leads to invasion of the basement membrane and cell proliferation associated with further angiogenesis. The most important step in the angiogenesis process is the translocation of Ang to the cell nucleus. Once Ang has been translocated to the nucleus, it enhances rRNA transcription by binding to the CT-rich (CTCTCTCTCTCTCTCTCCCTC) angiogenin binding element (ABE) within the upstream intergenic region of rDNA, which subsequently activates other angiogenic factors that induce angiogenesis. However, angiogenin is unique among the many proteins that are involved in angiogenesis in that it is also an enzyme with an amino acid sequence 33% identical to that of bovine pancreatic ribonuclease (RNase A).
=== Ma–Me === Alan MacDiarmid (1927–2007), American-New Zealand chemist who discovered conductive polymers, 2000 Nobel Prize in Chemistry Carolina Henriette Mac Gillavry (1904–1993), Dutch chemist and crystallographer known for discoveries on the use of diffraction in crystallography Roderick MacKinnon (born 1956), American biophsicist known for work on ion channels; 2003 Nobel Prize in Chemistry Pierre Macquer (1718–1784), French chemist known for Dictionnaire de chymie Rudolph A. Marcus (1923–2026), Canadian chemist known for work on the theory of electron transfer reactions; 1992 Nobel Prize in Chemistry Jacob A. Marinsky (1918–2005), American chemist, co-discovered the element promethium Jean Charles Galissard de Marignac (1817–1894), Swiss chemist who discovered ytterbium and co-discovered gadolinium Vladimir Vasilevich Markovnikov (1838–1904), Russian chemist known for Markovnikov's rule describing addition reactions of hydrogen halides and alkenes Tobin J. Marks (born 1944), American inorganic chemist and materials scientist known for work in polymerization catalysts Alan G.
== Research == Oral administration of LGD-4033 to cynomolgus monkeys at daily doses varying from 0 to 75 mg/kg over 13 weeks demonstrated significant body weight gain in both males and females. After 48 days, the 75 mg/kg dose testing was halted due to toxicity concerns, but this did not negatively impact development of the drug as this dose is significantly higher than the doses being utilized in a phase 2 clinical trial. Two phase 1 clinical trials of LGD-4033 have been conducted and reported. The first was a single-dose study published as a conference abstract in 2010 and the second was a multi-dose study published as a journal article in 2013. The multi-dose phase 1 trial published in 2013 reported that LGD-4033 dose-dependently improved lean body mass and muscle strength in 76 healthy young men over 21 days. It was generally well-tolerated in this study, with no significant adverse effects reported. A phase 2 clinical trial, initiated on 3 November 2016, consisted of 108 women and men recovering from hip fracture surgery. The randomized study participants received either placebo or varying doses of LGD-4033 over a period of 12 weeks, with improved lean body mass as the primary endpoint. Other endpoints included satisfactory results in terms of quality of life, safety, and pharmacokinetics. This study was completed and results reported in 2017 and 2018. In the trial, LGD-4033 dose-dependently improved lean body mass and muscle strength and was reported to be safe and well-tolerated.
Sources: en.wikipedia.org
1993/1445) Trade Effluent (Asbestos) (Scotland) Regulations 1993 (S.I. 1993/1446) Parking Attendants (Wearing of Uniforms) (London) Regulations 1993 (S.I. 1993/1450) Harbour Authorities (Variation of Constitution) Order 1993 (S.I. 1993/1451) Housing Renovation etc. Grants (Prescribed Forms and Particulars) (Amendment) (No. 2) Regulations 1993 (S.I. 1993/1452) County Council of Clwyd (A525 St Asaph—Rhyl Road, Rhuddlan Bypass Stage II) River Clwyd Bridge Scheme 1992 Confirmation Instrument 1993 (S.I. 1993/1456) Building Standards (Scotland) Amendment Regulations 1993 (S.I. 1993/1457) Borders Region (Electoral Arrangements) Order 1993 (S.I. 1993/1458) Road Traffic Act 1991 (Commencement No. 6 and Transitional Provisions) Order 1993 (S.I. 1993/1461) Hoole Island Junction (M53/A56) Chester (Detrunking) Order 1993 (S.I. 1993/1462) Road Traffic (Special Parking Areas) (The London Borough of Wandsworth) Order 1993 (S.I. 1993/1474) Removal and Disposal of Vehicles (Amendment) (No. 2) Regulations 1993 (S.I. 1993/1475) Food Protection (Emergency Prohibitions) (Paralytic Shellfish Poisoning) (No. 3) Order 1993 (S.I. 1993/1476) Plant Health Fees (Scotland) Order 1993 (S.I. 1993/1477) A11 Trunk Road (A505 Junction to Four Went Ways Improvement and Slip Roads) Order 1993 (S.I. 1993/1478) A11 Trunk Road (A505 Junction to Four Went Ways) (Detrunking) Order 1993 (S.I. 1993/1479) Council Tax Limitation (England) (Maximum Amounts) Order 1993 (S.I. 1993/1480) Food Protection (Emergency Prohibitions) (Paralytic Shellfish Poisoning) (No.4) Order 1993 (S.I.
Earlier estimates for snakebite vary from 1.2 to 5.5 million, with 421,000 to 2.5 million being envenomings, and causing 20,000 to 125,000 deaths. More recent modelling estimates that in 2019, about 63,400 people died globally from snakebite, with 51,100 of these deaths happening in India. Since reporting is not mandatory in much of the world, the data on the frequency of snakebites is not precise. Many people who survive bites have permanent tissue damage caused by venom, leading to disability. Most snake envenomings and fatalities occur in South Asia, Southeast Asia, and sub-Saharan Africa, with India reporting the most snakebite deaths of any country. Available evidence on the effect of climate change on the epidemiology of snakebite is limited but it is expected that there will be a geographic shift in the risk of snakebite: northwards in North America and southwards in South America and Mozambique, and increase in the incidence of bite in Sri Lanka. Most snakebites are caused by non-venomous snakes. Of the roughly 3,000 known species of snake found worldwide, only 15% are considered dangerous to humans. Snakes are found on every continent except Antarctica. The most diverse and widely distributed snake family, the colubrids, has approximately 700 venomous species, but only five genera—boomslangs, twig snakes, keelback snakes, green snakes, and slender snakes—have caused human fatalities. Worldwide, snakebites occur most frequently in the summer season when snakes are active and humans are outdoors.
=== International organizations === United Nations: UN Secretary General Antonio Guterres said Gaza was an integral part of a future Palestinian state. Amnesty International's Agnès Callamard condemned Trump's plan to take over Gaza and forcibly relocate Palestinians, calling it "outrageous and shameful." She said it would be a war crime and urged the global community to reject it and uphold Palestinian rights. International Coordination of Revolutionary Parties and Organizations: The ICOR released a statement condemning Trump's Gaza plan saying that it would be tantamount to a new Nakba. Holy See: The Catholic Patriarch of Jerusalem, Pierbattista Pizzaballa, on July 21, 2025, stated that the majority in Gaza will remain there: “First of all, they don’t know where to go, but they also don’t want to leave, because their roots are there, their home is there—or rather, they had their home there—and they want to rebuild it there. The Pope has been very clear on this: no population transfers; there will be no 'rivieras' in Gaza”.
Sources: en.wikipedia.org
In reaction, APHIS introduced more strict regulations for pharming field trials in the US in 2003. In 2005, Anheuser-Busch threatened to boycott rice grown in Missouri because of plans by Ventria Bioscience to grow pharm rice in the state. A compromise was reached, but Ventria withdrew its permit to plant in Missouri due to unrelated circumstances. The industry has slowly recovered, by focusing on pharming in simple plants grown in bioreactors and on growing GM crops in greenhouses. Some companies and academic groups have continued with open-field trials of GM crops that produce drugs. In 2006 Dow AgroSciences received USDA approval to market a vaccine for poultry against Newcastle disease, produced in plant cell culture – the first plant-produced vaccine approved in the U.S.
==== Cross-linking ==== Corneal collagen cross-linking is a developing treatment that aims to strengthen the cornea, however, according to a 2015 Cochrane review, there is insufficient evidence to determine if it is useful in keratoconus. In 2016, however, the FDA approved cross-linking surgery as a treatment for keratoconus and recommended that a registry system should be set-up to evaluate the long-term treatment effect. The Save Sight Keratoconus Registry is an international database of keratoconus patients that is tracking outcomes of cross-linking in patients with keratoconus.
===== MeSH D08.811.682.830 – succinate cytochrome c oxidoreductase ===== MeSH D08.811.682.830.249 – electron transport complex ii MeSH D08.811.682.830.249.500 – succinate dehydrogenase MeSH D08.811.682.830.500 – electron transport complex iii
=== Anraj Chabra === Anraj Chabra (Irfan Shamji) is a mild-mannered junior trader at Pierpoint working under Rishi, who frequently takes his anger out on him. Rishi uses Anraj's account to run a £300 million long on pound sterling against the US dollar, raising major flags at Pierpoint's risk management division (and jeopardizing Anraj's job and FCA license) until Rishi miraculously nets £18 million from the investment due to a last-minute tax cut by the UK government. Rishi also steals some of Anraj's money (claiming he is using it to bet on horse races) to gamble away at a casino. Anraj later admits that he is afraid to come to work because of Rishi's volatile behavior. Anraj and Sweetpea become friends over the course of their time at Pierpoint, in part due to their mutual frustration with Rishi. Anraj is briefly seen in series 4 attending the ALPHA conference, where Harper publicizes her findings on the fraudulent profits of fintech company Tender; he and Eric exchange a friendly glance.
Sources: en.wikipedia.org
Nicotinamide mononucleotide is a nucleotide intermediate in the biosynthesis of NAD+. It consists of nicotinamide attached to a ribose phosphate unit. NMN occurs naturally in cells and is present at low levels in some foods.
NMN is a direct precursor in the NAD+ salvage pathway. Enzymes called NMNAT convert NMN into NAD+, a coenzyme used in metabolism and cell signaling. Raising NMN may increase NAD+ in some experimental settings, but the effect depends on tissue and organism.
No. Nicotinamide riboside is a related compound that lacks the phosphate group present in NMN. Cells can convert nicotinamide riboside into NMN, and both compounds feed into NAD+ production through overlapping routes.
NMN stands for nicotinamide mononucleotide. It is a nucleotide composed of nicotinamide, ribose, and phosphate. In cells, it is an intermediate in NAD+ biosynthesis.